The medical community is excited with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 receptor that’s exhibiting significant potential in clinical trials for addressing obesity. Unlike some available weight loss approaches, retatrutide appears to provide a significant substantial reduction in body mass and benefit metabolic marke